BMO Upbeat on Neurogene with Maintained Outperform Rating and Stock Target Amid Gene Therapy Talks
Friday, 12 July 2024, 12:20
BMO's Steadfast Confidence
In a recent announcement, BMO has reiterated its confidence in Neurogene by maintaining its Outperform rating and stock target.
Positive Outlook Unchanged
The discussions surrounding gene therapy have not deterred BMO from projecting a bright future for Neurogene.
- Bullish Stance: BMO remains optimistic about Neurogene's potential performance in the market.
Investors may find assurance in BMO's unwavering support for Neurogene, indicating a positive sentiment towards the company's prospects.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.